DE10053155A1 - Treatment of psoriasis comprises administration of a multivitamin preparation containing vitamins B1, B2, B6, B12, C and E, nicotinamide, dexpanthenol, biotin and folic acid - Google Patents

Treatment of psoriasis comprises administration of a multivitamin preparation containing vitamins B1, B2, B6, B12, C and E, nicotinamide, dexpanthenol, biotin and folic acid

Info

Publication number
DE10053155A1
DE10053155A1 DE2000153155 DE10053155A DE10053155A1 DE 10053155 A1 DE10053155 A1 DE 10053155A1 DE 2000153155 DE2000153155 DE 2000153155 DE 10053155 A DE10053155 A DE 10053155A DE 10053155 A1 DE10053155 A1 DE 10053155A1
Authority
DE
Germany
Prior art keywords
vitamin
treatment
dexpanthenol
nicotinamide
biotin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE2000153155
Other languages
German (de)
Inventor
Erika Jungkeit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE2000153155 priority Critical patent/DE10053155A1/en
Publication of DE10053155A1 publication Critical patent/DE10053155A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12

Abstract

A multivitamin preparation containing vitamin B1, vitamin B2, nicotinamide, dexpanthenol, biotin, folic acid, vitamin B6, vitamin B12, vitamin C and vitamin E is used for the treatment of psoriasis.

Description

Schuppenflechte (Psoriasis) ist eine der häufigsten Hautkrankheiten, deren Gene­ se trotz zahlreicher Theorien bisher noch nicht aufgeklärt worden ist. Dement­ sprechend existiert auch keine verlässliche medikamentöse Therapie. Medika­ mentöse Hilfe setzt primär an den Symptomen der Krankheit an, um die an den Erkrankungsherden der Haut auftretenden Erscheinungen und insbesondere den damit verbundenen Schmerz zu mindern. Neben den hierfür geeigneten kortison­ haltigen Präparaten, die allerdings unerwünschte Nebenwirkungen erzeugen, sind zahlreiche ebenfalls zur lokalen Behandlung vorgesehene Mittel bekannt, die auf der Basis von Steinkohlenteer, Harnstoff, Salicylsäure, Selendisulfid, fein verteil­ tem Schwefel o. dgl. hergestellt sind. Es ist daher keine medikamentöse Be­ handlung bekannt, mit der die Beeinträchtigungen der Schuppenflechte möglichst nebenwirkungsfrei nachhaltig beseitigt werden können.Psoriasis is one of the most common skin diseases whose genes se has not yet been clarified despite numerous theories. Denial Speaking of which, there is also no reliable drug therapy. Medica mental help is primarily aimed at the symptoms of the disease in order to address the Disease foci of the skin appearing phenomena and in particular the to alleviate associated pain. In addition to the suitable cortisone containing preparations, which, however, produce undesirable side effects numerous remedies, also intended for local treatment, are known that are based on based on coal tar, urea, salicylic acid, selenium disulfide, finely divided tem sulfur o. The like. Are made. It is therefore not a medicinal product known act with which the impairments of psoriasis as possible can be eliminated sustainably without side effects.

Der Erfindung liegt daher die Problemstellung zugrunde, eine derartige medika­ mentöse Behandlung zu ermöglichen. The invention is therefore based on the problem of creating such a medicament to enable mental treatment.

Ausgehend von dieser Problemstellung wird erfindungsgemäß die Verwendung eines Multivitaminpräparats, enthaltend Vitamin B1, Vitamin B2, Nicotinamid, Dexpanthenol, Biotin, Folsäure, Vitamin B6, Vitamin B12, Vitamin C und Vitamin E, zur Behandlung der Schuppenflechte angegeben.Based on this problem, the invention specifies the use of a multivitamin preparation containing vitamin B 1 , vitamin B 2 , nicotinamide, dexpanthenol, biotin, folic acid, vitamin B 6 , vitamin B 12 , vitamin C and vitamin E, for the treatment of psoriasis.

Es ist in völlig überraschender Weise gefunden worden, dass ein derartiges Mul­ tivitaminpräparat in üblicher Dosierung und angewendet über mehrere Monate bereits nach einigen Wochen zu einer spürbaren Zurückentwicklung der Schup­ penflechte führt und nach wenigen Monaten bereits eine völlige Schmerzfreiheit eintritt, obwohl die Schuppenflechte zu diesem Zeitpunkt noch nicht völlig aus­ geheilt ist. Die völlige Ausheilung erfolgt nach einem deutlich längeren Zeitraum.It has been found in a completely surprising way that such a Mul tivitamin preparation in the usual dosage and used over several months After a few weeks, the dandruff started to regress noticeably Lichen leads and after a few months already a complete freedom from pain occurs even though the psoriasis has not yet completely resolved at this point is healed. Complete healing takes place after a significantly longer period of time.

Als Multivitaminpräparat sind Multivitaminkapseln verwendet worden, die unter der Bezeichnung Multibionta forte N der Firma Merck auf dem Markt sind. Die verwendeten Kapseln enthalten:
As a multivitamin preparation, multivitamin capsules have been used which are on the market under the name Multibionta forte N from Merck. The capsules used contain:

Thiamin-HCl (Vit. B1)Thiamine HCl (Vit. B 1 ) 15 mg15 mg Riboflavin (Vit. B2)Riboflavin (Vit. B 2 ) 12,5 mg12.5 mg NicotinamidNicotinamide 60 mg60 mg DexpanthenolDexpanthenol 10 mg10 mg BiotinBiotin 150 µg150 µg FolsäureFolic acid 500 µg500 µg Pyridoxin-HCl (Vit. B6)Pyridoxine HCl (Vit. B 6 ) 20 mg20 mg Cyanocobalamin (Vit. B12)Cyanocobalamin (Vit. B 12 ) 150 µg150 µg Ascorbinsäure (Vit. C)Ascorbic acid (Vit. C) 200 mg200 mg DL-TocopherolacetatDL-tocopherol acetate 74,5 mg (entspr. 50 mg Vit. E).74.5 mg (corresponding to 50 mg Vit. E).

Weitere Bestandteile der Zubereitung sind:
zum Teil gehärtete Pflanzenöle
mittelkettige Triglyceride
gelbes Wachs
Sojalecithin
Aromastoff
Gelantine
Glycerol
Anidrisorb
Farbstoffe Eisenoxide. Further components of the preparation are:
partly hydrogenated vegetable oils
medium chain triglycerides
yellow wax
Soy lecithin
Flavoring agent
Gelatin
Glycerol
Anidrisorb
Colorants iron oxides.

Das vorgesehene Anwendungsgebiet dieser Kapseln richtet sich auf Vitamin­ mangelsymptome, zu denen Schuppenflechte nicht gezählt wird. In Verbindung mit der Behandlung von Schuppenflechte oder anderen Hyper- und Dyskeratoso­ en ist als Vitaminwirkstoff allenfalls Vitamin A (Retinol) in hoher Dosierung (die deutlich über dem normalen Tagesbedarf eines Erwachsenen von 2 mg liegt) dis­ kutiert worden. Die erfindungsgemäß verwendeten Kapseln enthalten jedoch kein Vitamin A, sondern ausschließlich den oben angegebenen Vitaminkomplex. Die erfindungsgemäß festgestellte Wirksamkeit des Multivitaminpräparats ist daher mit den herkömmlichen Theorien nicht erklärbar.The intended application of these capsules is based on vitamins lack of symptoms, which does not include psoriasis. In connection with the treatment of psoriasis or other hyper- and dyskeratoso en is at most vitamin A (retinol) in high doses (the is well above the normal daily requirement of an adult of 2 mg) dis been cut. However, the capsules used according to the invention do not contain any Vitamin A, but only the vitamin complex given above. the The effectiveness of the multivitamin preparation determined according to the invention is therefore cannot be explained with conventional theories.

Die erfindungsgemäße Wirksamkeit des Multivitaminpräparats ist an drei zufällig ausgewählten Patientinnen festgestellt worden:The effectiveness of the multivitamin preparation according to the invention is random on three selected patients were found:

Beispiel 1example 1

Eine Patientin, knapp 50 Jahre alt, litt an einem Befall mit Schuppenflech­ te an den Innenflächen der Hände und Finger bis unter die Nägel sowie an den Fußsohlen. Die Haut war an den befallenen Stellen eingerissen, der Befall war mit starken Schmerzen verbunden.One patient, barely 50 years old, suffered from psoriasis te on the inner surfaces of the hands and fingers to under the nails as well the soles of the feet. The skin was torn in the affected areas, the The infestation was associated with severe pain.

Nach jahrelanger erfolgloser Behandlung durch verschiedene niedergelas­ sene Ärzte und in einer Universitätsklinik wurde die Einnahme eines Multi­ vitaminpräparats (Multibionta forte N-Kapseln; eine Kapsel pro Tag) be­ gonnen. Nach 1 ½ Monaten entwickelte sich die Schuppenflechte spürbar zurück. Nach etwa 4 Monaten trat Schmerzfreiheit ein. Die Haut war nicht mehr eingerissen, aber noch sehr empfindlich und gereizt. Bis zur totalen Ausheilung vergingen etwa 12 Monate. Seit dem ist die Haut zart und glatt und ohne irgendwelche Schäden.After years of unsuccessful treatment by various Niedergelas sene doctors and in a university hospital was taking a multi vitamin preparation (Multibionta forte N capsules; one capsule per day) be treat. After 1 ½ months the psoriasis developed noticeably return. After about 4 months there was no pain. The skin wasn't more torn, but still very sensitive and irritated. Up to the total Healing took about 12 months. Since then the skin is tender and smooth and without any damage.

Die Heilung ist allerdings an die weitere Einnahme der Multivitamin-Kapseln gekoppelt. Nach Absetzen des Multivitamin-Präparats bricht die Schuppenflechte nach ein paar Tagen an den früher befallenen Stellen wieder aus.The cure, however, depends on continuing to take the multivitamin capsules coupled. After stopping the multivitamin preparation, the psoriasis breaks after a few days in the previously infected areas again.

Beispiel 2Example 2

Patientin, Anfang 40, litt an einem extrem starken Befall von Schuppen­ flechte an beiden Füßen. Das Tragen normaler Schuhe war unmöglich. Die Haut war blutig und eingerissen. Ca. 2 Monate nach Beginn der Einnahme von Multibionta forte N-Kapseln (eine Kapsel pro Tag) war die Patientin schmerzfrei. Nach ca. 3 Monaten konnte sie erstmals wieder normale Schuhe tragen. Die Haut ist nicht mehr blutig und eingerissen und baut sich langsam wieder auf. Die Behandlung wird fortgesetzt.The patient, in her early 40s, suffered from extremely severe dandruff infestation braid on both feet. Wearing normal shoes was impossible. the Skin was bloody and torn. Approx. 2 months after starting the intake of Multibionta forte N capsules (one capsule per day) was the patient painless. After about 3 months she was able to return to normal for the first time Wearing shoes. The skin is no longer bloody and cracked and builds up slowly up again. Treatment continues.

Beispiel 3Example 3

Patientin, 32 Jahre, mit Befall von Schuppenflechte an beiden Armen mit stark juckenden Hautausschlägen. Zur Bekämpfung des Juckreizes fand eine Behandlung mit Cortisonsalbe statt.Patient, 32 years old, with psoriasis on both arms severe itchy rashes. Found to combat itching treatment with cortisone ointment instead.

Nach ca. 2 monatiger Einnahme von einer Kapsel Multibionta forte N pro Tag war der Juckreiz so stark zurückgegangen, dass die Cortisonsalbe ab­ gesetzt werden konnte. Die Rötung der befallenen Stellen ist zurückgegan­ gen. Die Behandlung wird fortgesetzt, ohne dass sonstige Medikamente eingenommen werden.After taking one capsule of Multibionta forte N pro for approx. 2 months By the day the itching had subsided so much that the cortisone ointment came off could be set. The reddening of the affected areas has decreased gen. Treatment continues without any other medication be taken.

Da Multivitaminpräparate der hier verwendeten Art im Normalfall keine Neben­ wirkungen haben, eignen sie sich für eine Dauerbehandlung bis zur möglichen endgültigen Ausheilung bzw. zur erneuten Behandlung, wenn Symptome der Schuppenflechte wieder auftreten sollten.Since multivitamin preparations of the type used here usually have no side effects have effects, they are suitable for long-term treatment up to the possible final healing or re-treatment if symptoms of Psoriasis should recur.

Claims (3)

1. Verwendung eines Multivitaminpräparats enthaltend Vitamin B1, Vitamin B2, Nicotinamid, Dexpanthenol, Biotin, Folsäure, Vitamin B6, Vitamin B12, Vitamin C und Vitamin E zur Behandlung der Schuppenflechte.1. Use of a multivitamin preparation containing vitamin B 1 , vitamin B 2 , nicotinamide, dexpanthenol, biotin, folic acid, vitamin B 6 , vitamin B 12 , vitamin C and vitamin E for the treatment of psoriasis. 2. Verwendung eines Multivitaminpräparats nach Anspruch 1 mit folgender Zu­ sammensetzung: Vitamin B1 15 mg Vitamin B2 12,5 mg Nicotinamid 60 mg Dexpanthenol 10 mg Biotin 150 µg Folsäure 500 µg Vitamin B6 20 mg Vitamin B12 150 µg Vitamin C 200 mg Vitamin E 50 mg.
2. Use of a multivitamin preparation according to claim 1 with the following composition: Vitamin B 1 15 mg Vitamin B2 12.5 mg Nicotinamide 60 mg Dexpanthenol 10 mg Biotin 150 µg Folic acid 500 µg Vitamin B 6 20 mg Vitamin B 12 150 µg vitamin C 200 mg Vitamin E. 50 mg.
3. Verwendung eines Multivitaminpräparates nach Anspruch 1 oder 2, das kein Vitamin A oder Vitamin A ≦ 2 mg enthält.3. Use of a multivitamin preparation according to claim 1 or 2, which is no Contains vitamin A or vitamin A ≦ 2 mg.
DE2000153155 2000-10-26 2000-10-26 Treatment of psoriasis comprises administration of a multivitamin preparation containing vitamins B1, B2, B6, B12, C and E, nicotinamide, dexpanthenol, biotin and folic acid Withdrawn DE10053155A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE2000153155 DE10053155A1 (en) 2000-10-26 2000-10-26 Treatment of psoriasis comprises administration of a multivitamin preparation containing vitamins B1, B2, B6, B12, C and E, nicotinamide, dexpanthenol, biotin and folic acid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2000153155 DE10053155A1 (en) 2000-10-26 2000-10-26 Treatment of psoriasis comprises administration of a multivitamin preparation containing vitamins B1, B2, B6, B12, C and E, nicotinamide, dexpanthenol, biotin and folic acid

Publications (1)

Publication Number Publication Date
DE10053155A1 true DE10053155A1 (en) 2002-05-08

Family

ID=7661173

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2000153155 Withdrawn DE10053155A1 (en) 2000-10-26 2000-10-26 Treatment of psoriasis comprises administration of a multivitamin preparation containing vitamins B1, B2, B6, B12, C and E, nicotinamide, dexpanthenol, biotin and folic acid

Country Status (1)

Country Link
DE (1) DE10053155A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117592A1 (en) * 2004-06-04 2005-12-15 Devlin, Daniel, J. Treatment of dermatological conditions
WO2006122685A1 (en) * 2005-05-17 2006-11-23 Greenleaf Srl Compositions for the treatment of psoriasis
US20090226482A1 (en) * 2008-03-04 2009-09-10 Hei Ling Helen Chan Herbal composition for treatment of insomnia and other related disorders and a method of preparing the same
CN112641923A (en) * 2020-12-24 2021-04-13 烟台心舒医药科技有限公司 Novel composition for treating psoriasis

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0055118A1 (en) * 1980-12-19 1982-06-30 Wallace Lysaght Arthritis treatment
NL9101406A (en) * 1991-08-20 1993-03-16 Vunderink Ate Method for the control and prevention of diseases caused by microorganisms.
EP0595005A1 (en) * 1992-09-14 1994-05-04 Vesta Medicines (Proprietary) Limited Pharmaceutical preparations for lowering homocysteine levels, containing vitamin B6, folic acid and vitamin B12
WO1994013252A1 (en) * 1992-12-10 1994-06-23 Hemogen, Inc. Method for stimulating production of heme oxygenase using vitamin b12
DE4319629A1 (en) * 1993-06-15 1994-12-22 Karsten Klingelhoeller Use of corrinoids for topical use in skin diseases
WO1999053907A2 (en) * 1998-04-16 1999-10-28 Mantynen Philip R Composition for treating psoriasis containing evening primrose oil and vitamins e and b

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0055118A1 (en) * 1980-12-19 1982-06-30 Wallace Lysaght Arthritis treatment
NL9101406A (en) * 1991-08-20 1993-03-16 Vunderink Ate Method for the control and prevention of diseases caused by microorganisms.
EP0595005A1 (en) * 1992-09-14 1994-05-04 Vesta Medicines (Proprietary) Limited Pharmaceutical preparations for lowering homocysteine levels, containing vitamin B6, folic acid and vitamin B12
WO1994013252A1 (en) * 1992-12-10 1994-06-23 Hemogen, Inc. Method for stimulating production of heme oxygenase using vitamin b12
DE4319629A1 (en) * 1993-06-15 1994-12-22 Karsten Klingelhoeller Use of corrinoids for topical use in skin diseases
WO1999053907A2 (en) * 1998-04-16 1999-10-28 Mantynen Philip R Composition for treating psoriasis containing evening primrose oil and vitamins e and b

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117592A1 (en) * 2004-06-04 2005-12-15 Devlin, Daniel, J. Treatment of dermatological conditions
WO2006122685A1 (en) * 2005-05-17 2006-11-23 Greenleaf Srl Compositions for the treatment of psoriasis
US20090226482A1 (en) * 2008-03-04 2009-09-10 Hei Ling Helen Chan Herbal composition for treatment of insomnia and other related disorders and a method of preparing the same
US8252290B2 (en) * 2008-03-04 2012-08-28 Vita Green Health Products Company Limited Herbal composition for treatment of insomnia and other related disorders and a method of preparing the same
CN112641923A (en) * 2020-12-24 2021-04-13 烟台心舒医药科技有限公司 Novel composition for treating psoriasis

Similar Documents

Publication Publication Date Title
Saller et al. Combined herbal preparation for topical treatment of Herpes labialis
DE60119534T2 (en) USE OF HYDROXYETHYL RUTOSIDES FOR THE TREATMENT OF DETECTION SYMPTOMS, SYMPTOMS OF ALLERGIC RHINITIS AND RESPIRATORY INFECTIONS
DE69930243T2 (en) TREATMENT OF IATROGENIC AND AGE-CONDITIONED BLOOD HIGH PRESSURE WITH VITAMIN B6 DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS USE THEREOF
DE69932073T2 (en) CYANOCOBALAMINE (VITAMIN B12) TREATMENT IN ALLERGIC DISEASES
DE3705151A1 (en) WARTS
DE60132008T2 (en) CYTYLMYRISTATE AND CETYLPALMITATE FOR THE TREATMENT OF ECCEMENTS AND / OR PSORIASIS
Rocha et al. Effect of honey and propolis, compared to acyclovir, against Herpes Simplex Virus (HSV)-induced lesions: A systematic review and meta-analysis
Romero-Cerecero et al. Pilot study that evaluated the clinical effectiveness and safety of a phytopharmaceutical elaborated with an extract of Ageratina pichinchensis in patients with minor recurrent aphthous stomatitis
EP0869807B1 (en) Use of a medicament and use of mixture of substances to produce a medicament
DE69730214T2 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF HERPES SIMPLEX
EP0037488A2 (en) Pharmaceutical composition for healing inflammatory and/or degenerative and/or atrophic mucous membranes
Simpson et al. Deanol in the treatment of tardive dyskinesia
EP0618797B1 (en) Pharmaceutical preparations containing bilobalid for the treatment of nervous tension and anxiety
US5639482A (en) Composition for control and prevention of diabetic retinopathy
DE10053155A1 (en) Treatment of psoriasis comprises administration of a multivitamin preparation containing vitamins B1, B2, B6, B12, C and E, nicotinamide, dexpanthenol, biotin and folic acid
DE60017251T2 (en) COMBINATION OF NICOTIC ACID OR NICOTINAMIDE WITH RIBOFLAVIN FOR THE TREATMENT OF PRURITUS AND INFLAMMATORY DISORDER
DE19726871C1 (en) Synergistic compositions for the selective control of tumor tissue
DE102005005086A1 (en) Natural remedies nutritional supplements combined preparation
DE69936779T2 (en) THE USE OF NGALI NUTRIOUS OIL FOR TREATING / REDUCING THE MANIFESTATIONS OF ARTHRITIS AND OTHER SIMILAR STATES
EP2803354B1 (en) Combination of polyacrylic acid and 2-amino-2-methylpropanol for use in the treatment of Herpes infections
JPH06199672A (en) Combination drug for local medical treatment for inflammatory dermatopathy containing chloramphenicol, gentamycin and nystatin as active ingredient
DD294864A5 (en) USE OF NAFTOPIDIL FOR THE THERAPY OF DYSURIA IN BENIGNER PROSTATE HYPERTROPHY
DE60025403T2 (en) KIT FOR THE TREATMENT OF MALARIA CONTAINING CHLOROQUIN AND BULAQUIN
DE19633446B4 (en) Medicinal products with lipid-lowering action
DE60210804T2 (en) USE OF PROPIONYL L-CARNITINE OR ITS PHARMACOLOGICALLY ACCEPTABLE SALTS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF LA PEYRONIE'S DISEASE

Legal Events

Date Code Title Description
OM8 Search report available as to paragraph 43 lit. 1 sentence 1 patent law
8139 Disposal/non-payment of the annual fee